dc.contributor.author | van der Graaf, WTA | |
dc.date.accessioned | 2017-04-21T16:54:24Z | |
dc.date.issued | 2016-07 | |
dc.identifier.citation | Lancet (London, England), 2016, 388 (10043), pp. 442 - 444 | |
dc.identifier.issn | 0140-6736 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/617 | |
dc.identifier.eissn | 1474-547X | |
dc.identifier.doi | 10.1016/s0140-6736(16)30788-7 | |
dc.format | Print-Electronic | |
dc.format.extent | 442 - 444 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Sarcoma | |
dc.subject | Soft Tissue Neoplasms | |
dc.title | Olaratumab in soft-tissue sarcomas. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1016/s0140-6736(16)30788-7 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2016-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Lancet (London, England) | |
pubs.issue | 10043 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical and Translational Sarcoma | |
pubs.publication-status | Published | |
pubs.volume | 388 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical and Translational Sarcoma | en_US |
dc.contributor.icrauthor | van der Graaf, Wilhelmina | |